FIELD: medicine. SUBSTANCE: method involves incubating urine sample under analysis at 37 C. Patient autoblood clot is used as substratum in incubating it with the urine sample. Then the blood clot is separated, and fibrinolytic activity of urine is determined by measuring optical density. EFFECT: simplified method.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING FIBRINOLYTIC BLOOD SYSTEM | 0 |
|
SU1492287A1 |
| METHOD FOR DETERMINATION OF RHEUMATOID ARTHRITIS TREATMENT EFFICACY IN CHILDREN | 0 |
|
SU1712884A1 |
| METHOD FOR DIAGNOSING CHRONIC PROSTATITIS | 1988 |
|
RU2067765C1 |
| USING MATRIC METALLOPROTEINASE-10 (MMP-10) FOR THROMBOLYTIC THERAPY | 2008 |
|
RU2489163C2 |
| METHOD OF DETERMINING PLASMIN FIBRINOLYTIC ACTIVITY IN BLOOD | 1996 |
|
RU2125266C1 |
| PHARMACEUTICAL COMPOSITION POSSESSING FIBRINOLYTIC EFFECT | 2007 |
|
RU2323001C1 |
| THE PROLONGED THROMBOLYTIC AGENT AND A METHOD OF ITS PREPARING | 1995 |
|
RU2121362C1 |
| METHOD FOR TREATING PYOTHORAX | 1992 |
|
RU2045280C1 |
| METHOD OF DIAGNOSIS OF THE COURSE OF CHRONIC PYELONEPHRITIS | 0 |
|
SU1575117A1 |
| PLASMINOGEN UROKINASE TYPE MODIFIED ACTIVATOR, DNA SEQUENCE, RECOMBINANT PLASMID, STRAIN-PRODUCER, METHOD FOR PREPARING PLASMINOGEN UROKINASE TYPE MODIFIED ACTIVATOR AND PHARMACEUTICAL COMPOSITION ELICITING THROMBOLYTIC EFFECT | 2001 |
|
RU2247777C2 |
